retatrutide vs orforglipron Eli Lilly's new trials for and Orforglipron: The Oral Non-Peptide GLP-1
Description
Questions remain on resolving cost, access and equity barriers and on whether to include those with diabetes in clinical trials
Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists
Generally, an individual may be a candidate for GLP-1 therapy if: They have a Body Mass Index (BMI) of 30 or higher
Obesity can promote the growth of breast cancer
Expert Opin Investig Drugs 21:4557
Pretreatment with semaglutide reduced the TNF- and IFN- response after LPS exposure [60]
